Product Reports Resources Pricing Login Book a demo

Protenus

Cybersecurity · Baltimore, United States · Founded 2014

Protenus - A new approach to protecting patient privacy and defending hospitals against HIPAA violations MoreLess

Established in 2014 by co-founders Nick Culbertson and Robert Lord, Protenus operates within the healthcare technology sector, providing artificial intelligence-driven solutions to mitigate risk for healthcare organizations. The founders' backgrounds are deeply rooted in the intelligence community and data science; Culbertson served as a US Army intelligence officer and Lord was a data scientist at the Johns Hopkins University Applied Physics Laboratory. This experience directly informs the company's approach to sifting through vast amounts of data to detect anomalous behavior, a skill set they translated from national security to patient privacy and security.

The company's core business revolves around its Patient Privacy Monitoring and Drug Diversion Surveillance platform. This platform helps hospitals and health systems protect sensitive patient data and prevent the theft of controlled substances. Protenus serves a client base of healthcare organizations, offering them tools to ensure compliance with regulations like HIPAA and to combat the growing issue of drug diversion within their facilities. The business model is based on providing these risk-reduction solutions as a service, presumably through a subscription or licensing fee structure. The platform analyzes every access to patient data within a hospital's electronic health record system, using AI to identify inappropriate access patterns. For drug diversion, the system scrutinizes the entire medication lifecycle—from procurement to administration—to detect suspicious activities that could indicate theft for personal use or sale.

Protenus has achieved several key milestones, including securing multiple rounds of funding to fuel its growth and product development. For instance, the company raised $21 million in a Series D funding round in 2021, bringing its total funding to over $50 million at the time. Throughout its history, Protenus has garnered industry recognition, being named to various prestigious lists such as the Forbes list of America's Best Startup Employers and Modern Healthcare's Best Places to Work. Keywords: healthcare AI, patient privacy monitoring, drug diversion surveillance, healthcare compliance, risk reduction, electronic health records, data security, health data analytics, HIPAA, controlled substances

Talent graph

Protenus's talent

Book a demo to see the people
Team profiled 12 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

11 investors on Protenus's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Seed 1 investor entered at this stage
Dreamit Ventures
Series A 6 investors entered at this stage
Arthur Ventures
Kaiser Permanente Ventures
Kaiser Permanente
LionBird
F-Prime
Cognosante
Series B+ 4 investors entered at this stage
Providence Ventures
Transformation Capital
Gaingels
MemorialCare Innovation Fund

Global footprint

Where Protenus has talent and traffic

Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

What the market is saying about Protenus

An AI-synthesized read of the highest-engagement posts about Protenus on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Protenus on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.